Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

A genetic basis of congenital isolated hypogonadotropic hypogonadism (CHH) can be
defined in almost 50% of cases, albeit not necessarily the complete genetic basis. Next …

Acromegaly is typically caused by a growth hormone–secreting pituitary adenoma, driving
excess secretion of insulin-like growth factor 1. Acromegaly may result in a variety of …

Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and
lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical …

First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical
treatment of acromegaly, however the percentage of patients controlled with these drugs …

Background: Acromegaly results from a persistent excess in growth hormone with clinical
features that may be subtle or severe. The most common cause of acromegaly is a pituitary …

GH-secreting pituitary adenomas can be hypo-, iso-or hyperintense on T2-weighted MRI
sequences. We conducted the current multicenter study in a large population of patients with …

Acromegaly is associated with high morbidity and elevated mortality when not adequately
treated. Surgery is the first-line treatment for most patients as it is the only one that can lead …

Non-syndromic pituitary gigantism can result from AIP mutations or the recently identified
Xq26. 3 microduplication causing X-linked acrogigantism (XLAG). Within Xq26. 3, GPR101 …